Literature DB >> 2897133

Radioimmunotherapy with alpha-particle-emitting immunoconjugates.

R M Macklis1, B M Kinsey, A I Kassis, J L Ferrara, R W Atcher, J J Hines, C N Coleman, S J Adelstein, S J Burakoff.   

Abstract

Alpha particles are energetic short-range ions whose higher linear energy transfer produces extreme cytotoxicity. An alpha-particle-emitting radioimmunoconjugate consisting of a bismuth-212-labeled monoclonal immunoglobulin M specific for the murine T cell/neuroectodermal surface antigen Thy 1.2 was prepared. Analysis in vitro showed that the radioimmunoconjugate was selectively cytotoxic to a Thy 1.2+ EL-4 murine tumor cell line. Approximately three bismuth-212-labeled immunoconjugates per target cell reduced the uptake of [3H]thymidine by the EL-4 target cells to background levels. Mice inoculated intraperitoneally with EL-4 cells were cured of their ascites after intraperitoneal injection of 150 microcuries of the antigen-specific radioimmunoconjugate, suggesting a possible role for such conjugates in intracavitary cancer therapy.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897133     DOI: 10.1126/science.2897133

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  32 in total

1.  Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu.

Authors:  J M Connett; C J Anderson; L W Guo; S W Schwarz; K R Zinn; B E Rogers; B A Siegel; G W Philpott; M J Welch
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 2.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

Review 3.  Radiopharmaceuticals: state of the art.

Authors:  A M Verbruggen
Journal:  Eur J Nucl Med       Date:  1990

4.  Automated cassette-based production of high specific activity [203/212Pb]peptide-based theranostic radiopharmaceuticals for image-guided radionuclide therapy for cancer.

Authors:  Mengshi Li; Xiuli Zhang; Thomas P Quinn; Dongyoul Lee; Dijie Liu; Falk Kunkel; Brian E Zimmerman; Daniel McAlister; Keith Olewein; Yusuf Menda; Saed Mirzadeh; Roy Copping; Frances L Johnson; Michael K Schultz
Journal:  Appl Radiat Isot       Date:  2017-05-10       Impact factor: 1.513

5.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

Review 6.  Antibody mediated targeting of radioisotopes, drugs and toxins in diagnosis and treatment.

Authors:  C H Ford; V J Richardson; V S Reddy
Journal:  Indian J Pediatr       Date:  1990 Jan-Feb       Impact factor: 1.967

7.  (211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

Authors:  Christopher R Burtner; Devikha Chandrasekaran; Erlinda B Santos; Brian C Beard; Jennifer E Adair; Donald K Hamlin; D Scott Wilbur; Brenda M Sandmaier; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

Review 8.  Therapeutic radionuclides: biophysical and radiobiologic principles.

Authors:  Amin I Kassis
Journal:  Semin Nucl Med       Date:  2008-09       Impact factor: 4.446

9.  MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.

Authors:  George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico
Journal:  J Nucl Med       Date:  2010-01-15       Impact factor: 10.057

10.  Cancer stem cell targeting using the alpha-particle emitter, 213Bi: mathematical modeling and feasibility analysis.

Authors:  George Sgouros; Hong Song
Journal:  Cancer Biother Radiopharm       Date:  2008-02       Impact factor: 3.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.